Steward Partners Investment Advisory’s Trevi Therapeutics TRVI Stock Holding History

Steward Partners Investment Advisory’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$615K	Buy	51,525 +7,430	+17%	+$83.2K	﹤0.01%	1408
2025 Q4	$552K	Buy	44,095 +12,500	+40%	+$144K	﹤0.01%	1369
2025 Q3	$289K	Buy	31,595 +19,595	+163%	+$147K	﹤0.01%	1673
2025 Q2	$65.6K	Buy	12,000 +2,000	+20%	+$12.4K	﹤0.01%	2333
2025 Q1	$62.9K	Buy	+10,000	New	+$47.7K	﹤0.01%	2261
2024 Q2	–	Sell	-25	Closed	-$86	–	3720
2024 Q1	$86	Hold	25	–	–	﹤0.01%	3508
2023 Q4	$34	Buy	+25	New	+$38	﹤0.01%	3469

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Steward Partners Investment Advisory's TRVI Position: Q1 2026 in Review

Steward Partners Investment Advisory increased its Trevi Therapeutics (TRVI) stake by 17% in Q1 2026, buying an estimated $83.2K and bringing the position to 51,525 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Steward Partners Investment Advisory first reported a position in TRVI in Q4 2023 and has held it in 7 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

Steward Partners Investment Advisory held 51,525 shares of Trevi Therapeutics worth $615K as of Q1 2026.
Steward Partners Investment Advisory bought 7,430 Trevi Therapeutics shares in Q1 2026, an estimated $83.2K.
Trevi Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #1408 holding.
Steward Partners Investment Advisory first reported a position in Trevi Therapeutics in Q4 2023 and has held it in 7 quarters since.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.